Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
Elbasvir
50
CHF
CHF 50.00
In stock
AG-CR1-3729-M0011 mgCHF 50.00
AG-CR1-3729-M0055 mgCHF 145.00
AG-CR1-3729-M02525 mgCHF 435.00
| Product Details | |
|---|---|
| Synonyms | MK-8742 |
| Product Type | Chemical |
| Properties | |
| Formula |
C49H55N9O7 |
| MW | 882.0 |
| CAS | 1370468-36-2 |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | White to off-white solid. |
| Solubility | Soluble in DMSO (20mg/ml), DMF (25mg/ml) or ethanol (25mg/ml). |
| Identity | Determined by 1H-NMR. |
| InChi Key | BVAZQCUMNICBAQ-ISSDNXAZSA-N |
| Smiles | O=C(N1CCCC1C2=NC=C(C3=CC4=C(N(C5=C4)[C@@H](OC6=C5C=CC(C7=CN=C(N7)[C@@H]8CCCN8C([C@H](C(C)C)NC(OC)=O)=O)=C6)C9=CC=CC=C9)C=C3)N2)[C@@H](NC(OC)=O)C(C)C |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Keep cool and dry. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
- Elbasvir is a direct-acting antiviral drug that potently inhibits hepatitis C virus (HCV) non-structural protein 5A (NS5A). NS5A is essential for HCV RNA synthesis and viral assembly, and elbasvir inhibits the assembly of new viral replicase complexes when used at a concentration of 50 pM.
- It exhibits potent inhibitory activity against a broad range of HCV genotypes.
- Formulations containing elbasvir have been used alone and in combination with NS3/4A protease inhibitors in the treatment of HCV.
- Identified as a potential inhibitor of SARS-CoV-2, responsible for COVID-19.
Product References
- Discovery of MK-8742: An HCV NS5A Inhibitor With Broad Genotype Activity: C.A. Coburn, et al.; ChemMedChem 8, 1930 (2013)
- Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors: D.R. McGivern, et al.; Gastroenterology 147, 453 (2014) (Review)
- Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir: R. Liu, et al.; Antimicrob. Agents Chemother. 59, 6922 (2015)
- The combination of grazoprevir, a Hepatitis C virus (HCV) NS3/4A protease inhibitor, and elbasvir, an HCV NS5A inhibitor, demonstrates a high genetic barrier to resistance in HCV genotype 1a replicons: F.C. Lahser, et al.; Antimicrob. Agents Chemother. 60, 2954 (2016)
- Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C: A.M. Bell, et al.; Int. J. Hepatol. 2016, 3852126 (2016) (Review)
- Antiviral activity and resistance analysis of NS3/4A protease inhibitor grazoprevir and NS5A inhibitor elbasvir in Hepatitis C virus GT4 replicons: E. Asante-Appiah, et al.; Antimicrob. Agents Chemother. 61, e00363 (2017)
- Fast Identification of Possible Drug Treatment of Coronavirus Disease -19 (COVID-19) Through Computational Drug Repurposing Study: J. Wang; Preprints (2020)
- Computational target-based drug repurposing of elbasvir, an antiviral drug predicted to bind multiple SARS-CoV-2 proteins: M. Balasubramaniam & R.J. Shmookler Reis; ChemRxiv (Preprint) (2020)
Related Products
